LL-37 Dosing Protocol: Antimicrobial Research Guide

Also known as: Cathelicidin antimicrobial peptide

immunity

Research Reference Only

This information is for educational purposes only. LL-37 is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

LL-37 is the only known human cathelicidin antimicrobial peptide. It plays a crucial role in innate immunity and has been studied for its antimicrobial, immunomodulatory, and wound healing properties.

Mechanisms of Action

Direct antimicrobial activity against bacteria, viruses, fungi

Modulates immune cell chemotaxis

Promotes wound healing

Regulates inflammatory responses

Influences angiogenesis

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
Antimicrobial Study	in vitro	Variable	N/A	N/A	Topical/Inhalation	in vitro

Important Warnings

Safety Considerations

Limited human clinical data
May trigger inflammatory responses in some contexts
Research primarily in vitro and animal models